Related Experiment Video
Updated: Oct 19, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Cardiometabolic outcomes in children and adolescents with West syndrome
Inbar Gilboa1,2, Galit Israeli1,2, Avivit Brener1,2
1Pediatric Endocrinology and Diabetes Unit, Dana-Dwek Children's Hospital, Tel Aviv Sourasky Medical Center, 6423906, Tel Aviv, Israel.
Insights
Infants with West syndrome exhibit significant cardiometabolic issues, particularly those treated with adrenocorticotropic hormone (ACTH). Monitoring is crucial as these issues decrease over time.
Area of Science:
- Pediatric Neurology
- Endocrinology
- Metabolic Disorders
Background:
- West syndrome is a severe infantile convulsive disorder.
- Adrenocorticotropic hormone (ACTH) effectively treats spasms but its long-term metabolic effects in children are unknown.
Purpose of the Study:
- To investigate the cardiometabolic outcomes in children with West syndrome.
- To compare outcomes between ACTH-treated and non-ACTH-treated patients.
Main Methods:
- Observational study of 117 children with West syndrome (1995-2019).
- Assessed prevalence of obesity, hypertension, and dyslipidemia across different age groups.
- Compared cardiometabolic derangements between ACTH-treated and non-ACTH-treated groups.
Main Results:
- High rates of metabolic derangements observed in infancy, including obesity, hypertension, and dyslipidemia.
- ACTH-treated infants showed higher weight, weight-to-length z-scores, and triglyceride levels.
- Cardiometabolic abnormalities were more pronounced in infancy and tended to decrease with age.
Conclusions:
- Children with West syndrome have an increased prevalence of cardiometabolic derangements.
- These derangements are more common in infants and those treated with ACTH.
- Regular monitoring for cardiometabolic issues is recommended for these children.
Background:
West syndrome is a convulsive disorder of infancy with unique seizures and a characteristic background electroencephalograph pattern. Adrenocorticotropic hormone (ACTH) is effective in spasm cessation, yet metabolic consequences of this therapeutic agent in childhood have not been published.
Methods:
In this observational study we explored the cardiometabolic outcomes of 117 children with West syndrome (78 ACTH-treated and 39 non-ACTH-treated) monitored at a single medical center from 1995 to 2019 (median follow-up 7.2 years). Outcomes included the prevalence of cardiometabolic derangements (obesity, hypertension, and dyslipidemia) during infancy (< 2 years), early childhood (2-6 years), and childhood/adolescence (6-18 years).
Results:
The rates of metabolic derangements during infancy in the West syndrome cohort were high compared to childhood/adolescence (obesity 27.3 % vs. 3.3 %, [p = 0.010], diastolic hypertension 48.8 % vs. 5.1 % [p < 0.001], hypertriglyceridemia 71 % vs. 40 % [p = 0.008], low high-density lipoprotein cholesterol [HDL-c] 54.2 % vs. 12.9 % [p = 0.001], and elevated triglycerides/HDL-c ratios 62.5 % vs. 12.9 % [p < 0.001]). The proportion of systolic and/or diastolic blood pressure levels categorized as hypertensive was 58.5 % during infancy, 48.1 % during early childhood, and 26.3 % during childhood/adolescence. ACTH-treated patients had higher weight and weight-to-length z-scores and higher triglyceride levels during infancy compared to non-ACTH-treated patients (p = 0.008, p = 0.001, and p = 0.037, respectively), and higher triglyceride levels during early childhood (p = 0.050), with no significant group differences during childhood/adolescence.
Conclusions:
Children with West syndrome apparently have an increased prevalence of cardiometabolic derangements more pronounced in infants and in ACTH-treated patients. These findings highlight the need to monitor these children for cardiometabolic derangements, even though these cardiometabolic abnormalities are transitory and tend to decrease with time. The health implications of cardiometabolic derangements during critical windows of growth and development warrant further investigation.
More Related Videos
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Diabetes Mellitus: Type 2 and Gestational
Coronary Artery Disease I: Introduction
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy

